Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. Our lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1). For more information about Entrada, please visit www.entradatx.com.